About
The Journal "Obstetrics and Gynecology"Journal HistoryAims and ScopePolicies on Conflict of Interest, Human and Animal Rights, and Informed ConsentEditorial ProcessData sharing statementAdvertising PolicyThe Process for Handling Cases Requiring Corrections, Retractions, and Editorial Expressions of ConcernEditorial BoardEditorial CounsilInformation for ProfessionalsNewsContacts
ArchiveEthical StandardsSubscription
For authors
InstructionsInformed consent policyContract offerEASE GuidelinesICJME CriteriaWAME Recommendations on ChatGPT and Chatbots in Relation to Scholarly Publications
Reviewing
Procedure for reviewingReviewers 2023-2024
ISSN 0300-9092 (Print)
ISSN 2412-5679 (Online)
About
The Journal "Obstetrics and Gynecology"Journal HistoryAims and ScopePolicies on Conflict of Interest, Human and Animal Rights, and Informed ConsentEditorial ProcessData sharing statementAdvertising PolicyThe Process for Handling Cases Requiring Corrections, Retractions, and Editorial Expressions of ConcernEditorial BoardEditorial CounsilInformation for ProfessionalsNewsContacts
ArchiveEthical StandardsSubscription
For authors
InstructionsInformed consent policyContract offerEASE GuidelinesICJME CriteriaWAME Recommendations on ChatGPT and Chatbots in Relation to Scholarly Publications
Reviewing
Procedure for reviewingReviewers 2023-2024
Logout
Obstetrics and Gynegology2026№8

Consensus statement on results of interdisciplinary Expert Council with international participation on personalized prescription of hormone replacement therapy/menopausal hormone therapy after treatment of malignant tumors of female reproductive system

DOI
https://dx.doi.org/10.18565/aig.2026.8.215-223

June 7–8, 2026, Moscow

For citation: Consensus statement on results of interdisciplinary Expert Council with international participation 
on personalized prescription of hormone replacement therapy/menopausal hormone therapy after treatment 
of malignant tumors of female reproductive system.
Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2026; (8): 215-223 (in Russian)
https://dx.doi.org/10.18565/aig.2026.217

Full text (in Russian)

References

  1. Siegel R.L., Kratzer T.B., Wagle N.S., Sung H., Jemal A. Cancer statistics, 2026. CA Cancer J. Clin. 2026; 76(1): e70043. https://dx.doi.org/10.3322/caac.70043
  2. Rocca W.A., Mielke M.M., Gazzuola Rocca L., Stewart E.A. Premature or early bilateral oophorectomy: a 2021 update. Climacteric. 2021; 24(5): 466-73. https://dx.doi.org/10.1080/13697137.2021.1893686
  3. Rocca W.A., Grossardt B.R., Shuster L.T. Oophorectomy, estrogen, and dementia: a 2014 update. Mol. Cell. Endocrinol. 2014; 389(1-2): 7-12. https://dx.doi.org/10.1016/j.mce.2014.01.020
  4. Panay N., Fenton A., Hamoda H., Hillard T., Islam R., Pedder H. et al.; IMS Recommendations Writing Group. International Menopause Society (IMS) recommendations and key messages on women's midlife health and menopause. Climacteric. 2025; 28(6): 634-56. https://dx.doi.org/10.1080/13697137.2025.2585487
  5. Taylor A., Clement K., Hillard T., Sassarini J., Ratnavelu N., Baker-Rand H. et al. British Gynaecological Cancer Society and British Menopause Society guidelines: management of menopausal symptoms following treatment of gynaecological cancer. Post Reprod. Health. 2024; 30(4): 256-79. https://dx.doi.org/10.1177/20533691241286666
  6. Rees M., Angioli R., Coleman R.L., Glasspool R., Plotti F., Simoncini T. et al. European Menopause and Andropause Society (EMAS) and International Gynecologic Cancer Society (IGCS) position statement on managing the menopause after gynecological cancer: focus on menopausal symptoms and osteoporosis. Maturitas. 2020; 134: 56-61. https://dx.doi.org/10.1016/j.maturitas.2020.01.005
  7. Sanft T., Day A.T., Ansbaugh S.M., Ariza-Heredia E.J., Armenian S., Baker K.S. et al. NCCN Guidelines® Insights: Survivorship, Version 2.2025. J. Natl. Compr. Canc. Netw. 2025; 23(6): 208-17. https://dx.doi.org/10.6004/jnccn.2025.0028
  8. ESHRE, ASRM, CREWHIRL and IMS Guideline Group on POI; Panay N., Anderson R.A., Bennie A., Cedars M., Davies M., Ee C. et al. Evidence-based guideline: premature ovarian insufficiency. Climacteric. 2024; 27(6): 510-20. https://dx.doi.org/10.1080/13697137.2024.2423213
  9. Gao S., Wang J., Li Z., Wang T., Wang J. Global trends in incidence and mortality rates of endometrial cancer among individuals aged 55 years and above from 1990 to 2021: An analysis of the global burden of disease. Int. J. Womens Health. 2025; 17: 651-62. https://dx.doi.org/10.2147/IJWH.S499435
  10. Cosgrove C.M., Tritchler D.L., Cohn D.E., Mutch D.G., Rush C.M., Lankes H.A. et al. An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer. Gynecol. Oncol. 2018; 148: 174-80. https://dx.doi.org/10.1016/j.ygyno. 2017.10.037
  11. Léon-Castillo A. Update in the molecular classification of endometrial carcinoma. Int. J. Gynecol. Cancer. 2023; 33(3): 333-42. https://dx.doi.org/10.1136/ijgc-2022-003772
  12. Arciuolo D., Travaglino A., Raffone A., Raimondo D., Santoro A., Russo D. et al. TCGA molecular prognostic groups of endometrial carcinoma: POLE-mutated, MMR-deficient, p53-abnormal and NSMP subtypes. Int. J. Mol. Sci. 2022; 23(19): 11684. https://dx.doi.org/10.3390/ijms231911684
  13. Parra-Herran C., Lerner-Ellis J., Xu B., Khalouei S., Bassiouny D., Cesari M. et al. Molecular-based classification algorithm for endometrial carcinoma categorizes ovarian endometrioid carcinoma into prognostically significant groups. Mod. Pathol. 2017; 30(12): 1748-59. https://dx.doi.org/10.1038/modpathol.2017.81
  14. Concin N., Matias-Guiu X., Cibula D., Colombo N., Creutzberg C.L., Ledermann J. et al. ESGO-ESTRO-ESP guidelines for the management of patients with endometrial carcinoma: update 2025. Lancet Oncol. 2025; 26(8): e423-e435. https://dx.doi.org/10.1016/S1470-2045(25)00167-6
  15. Министерство здравоохранения Российской Федерации. Клинические рекомендации. Рак тела матки и саркомы матки. 2024. Доступно по: https://cr.minzdrav.gov.ru/view-cr/460_4 [Ministry of Health of the Russian Federation. Clinical guidelines. Uterine body cancer and uterine sarcomas. 2024. Available at: https://cr.minzdrav.gov.ru/view-cr/460_4 (in Russian)].
  16. Shim S.H., Lee S.J., Kim S.N. Effects of hormone replacement therapy on the rate of recurrence in endometrial cancer survivors: A meta-analysis. Eur. J. Cancer. 2014; 50(9): 1628-37. https://dx.doi.org/10.1016/j.ejca.2014.03.006.
  17. Edey K.A., Rundle S., Hickey M. Hormone replacement therapy for women previously treated for endometrial cancer. Cochrane Database Syst. Rev. 2018; 5(5): CD008830. https://dx.doi.org/10.1002/14651858.CD008830.pub3
  18. Barakat R.R., Bundy B.N., Spirtos N.M., Bell J., Mannel R.S.; Gynecologic Oncology Group Study. Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Gynecologic Oncology Group Study. J. Clin. Oncol. 2006; 24(4): 587-92. https://dx.doi.org/10.1200/JCO.2005.02.8464
  19. Урманчеева А.Ф., Михайлюк Г.И., Ульрих Е.А. Заместительная гормональная терапия в реабилитации больных раком эндометрия после радикального лечения. Журнал акушерства и женских болезней. 2004; 53(4): 53-8. [Urmancheyeva A.F., Mikhailuk G.I., Ulrikh E.A. Replacement hormonal therapy for rehabilitation of patients with endometrial cancinoma after radical treatment. Journal of Obstetrics and Women's Diseases. 2004; 53(4): 53-8 (in Russian)].
  20. Wei Y.F., Ning L., Xu Y.L., Ma J., Li D.R., Feng Z.F. et al. Worldwide patterns and trends in ovarian cancer incidence by histological subtype: a population-based analysis from 1988 to 2017. EClinicalMedicine. 2025; 79: 102983. https://dx.doi.org/10.1016/j.eclinm.2024.102983
  21. Eeles R.A., Morden J.P., Gore M., Mansi J., Glees J., Wenczl M. et al. Adjuvant hormone therapy may improve survival in epithelial ovarian cancer: Results of the AHT randomized trial. J. Clin. Oncol. 2015; 33(35): 4138-44. https://dx.doi.org/10.1200/JCO.2015.60.9719
  22. Mascarenhas C., Lambe M., Bellocco R., Bergfeldt K., Riman T., Persson I. et al. Use of hormone replacement therapy before and after ovarian cancer diagnosis and ovarian cancer survival. Int. J. Cancer. 2006; 119(12): 2907-15. https://dx.doi.org/10.1002/ijc.22218
  23. Power L., Lefas G., Lambert P., Kim D., Evaniuk D., Lotocki R. et al. Hormone use after nonserous epithelial ovarian cancer: Overall and disease-free survival. Obstet. Gynecol. 2016; 127(5): 837-47. https://dx.doi.org/10.1097/AOG.0000000000001396
  24. Achimaș-Cadariu P.A., Păun D.L., Pașca A. Impact of hormone replacement therapy on the overall survival and progression free survival of ovarian cancer patients: a systematic review and meta-analysis. Cancers. 2023; 15(2): 356. https://dx.doi.org/10.3390/cancers15020356
  25. Bray F., Laversanne M., Sung H., Ferlay J., Siegel R.L., Soerjomataram I. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2024; 74(3): 229-263. https://dx.doi.org/10.3322/caac.21834
  26. Cohen C.M., Wentzensen N., Castle P.E., Schiffman M., Zuna R., Arend R.C. et al. Racial and ethnic disparities in cervical cancer incidence, survival, and mortality by histologic subtype. J. Clin. Oncol. 2023; 41(5): 1059-68. https://dx.doi.org/10.1200/JCO.22.01424
  27. Xing B., Guo J., Sheng Y., Wu G., Zhao Y. Human papillomavirus-negative cervical cancer: a comprehensive review. Front. Oncol. 2021; 10: 606335. https://dx.doi.org/10.3389/fonc.2020.606335
  28. Vargiu V., Amar I.D., Rosati A., Dinoi G., Turco L.C., Capozzi V.A. et al. Hormone replacement therapy and cervical cancer: a systematic review of the literature. Climacteric. 2021; 24(2): 120-7. https://dx.doi.org/10.1080/13697137.2020.1826426
  29. Everhov Å.H., Nyberg T., Bergmark K., Citarella A., Rådestad A.F., Hirschberg A.L. et al. Hormone therapy after uterine cervical cancer treatment: a Swedish population-based study. Menopause. 2015; 22(6): 633-9. https://dx.doi.org/10.1097/GME.0000000000000357
  30. Park K.J. Cervical adenocarcinoma: integration of HPV status, pattern of invasion, morphology and molecular markers into classification. Histopathology. 2020; 76(1): 112-27. https://dx.doi.org/10.1111/his.13995
  31. Ploch E. Hormonal replacement therapy in patients after cervical cancer treatment. Gynecol. Oncol. 1987; 26(2): 169-77. https://dx.doi.org/10.1016/0090-8258(87)90270-8
  32. Harbeck N., Penault-Llorca F., Cortes J., Gnant M., Houssami N., Poortmans F. et al. Breast cancer. Nat. Rev. Dis. Primers. 2019; 5(1): 66. https://dx.doi.org/10.1038/s41572-019-0111-2
  33. Holmberg L., Anderson H.; HABITS Steering and Data Monitoring Committees. HABITS (hormonal replacement therapy after breast cancer—is it safe?), a randomised comparison: trial stopped. Lancet. 2004; 363(9407): 453-5. https://dx.doi.org/10.1016/S0140-6736(04)15493-7
  34. Kenemans P., Bundred N.J., Foidart J.M., Kubista E., von Schoultz B., Sismondi P. et al.; LIBERATE Study Group. Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. Lancet Oncol. 2009; 10(2): 135-46. https://dx.doi.org/10.1016/S1470-2045(08)70341-3
  35. Cold S., Cold F., Jensen M.B., Cronin-Fenton D., Christiansen P., Ejlertsen B. Systemic or vaginal hormone therapy after early breast cancer: a Danish observational cohort study. J. Natl. Cancer Inst. 2022; 114(10): 1347-54. https://dx.doi.org/10.1093/jnci/djac112
  36. Beste M.E., Kaunitz A.M., McKinney J.A., Sanchez-Ramos L. Vaginal estrogen use in breast cancer survivors: a systematic review and meta-analysis of recurrence and mortality risks. Am. J. Obstet. Gynecol. 2025; 232(3):262-270.e1. https://dx.doi.org/10.1016/j.ajog.2024.10.054
By continuing to use our site, you consent to the processing of cookies that ensure the proper functioning of the site.